NCT07211633 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) | Biotech Hunter

Enrollment

360

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Relapsing Multiple Sclerosis

Interventions

BIOLOGICAL

Ublituximab

Administered as an IV infusion.

BIOLOGICAL

Ublituximab

Administered as an SC injection.

Trial Locations (10)

14029

RECRUITING

TG Therapeutics Investigational Trial Site, Cherkasy

21001

RECRUITING

TG Therapeutics Investigational Trial Site, Vinnytsia

21009

RECRUITING

TG Therapeutics Investigational Trial Site, Odesa

46027

RECRUITING

TG Therapeutics Investigational Trial Site, Ternopil

76000

RECRUITING

TG Therapeutics Investigational Trial Site, Ivano-Frankivsk

76018

RECRUITING

TG Therapeutics Investigational Trial Site, Ivano-Frankivsk

76493

RECRUITING

TG Therapeutics Investigational Trial Site, Ivano-Frankivsk

79000

RECRUITING

TG Therapeutics Investigational Trial Site, Lviv

79010

RECRUITING

TG Therapeutics Investigational Trial Site, Lviv

03037

RECRUITING

TG Therapeutics Investigational Trial Site, Kyiv

All Listed Sponsors

lead

TG Therapeutics, Inc.

INDUSTRY